Applying IsoPSA’s Predictive Power to Guide Patient Monitoring

Join your LUGPA peers for this Innovation Theater On-Demand program, "Applying IsoPSA’s Predictive Power to Guide Patient Monitoring,” sponsored by IsoPSA. This On-Demand webinar discusses published data demonstrating the ability of a single IsoPSA result to predict risk for csPCa over 30 months, enabling more informed patient monitoring and better shared decision-making.

 
View Webinar

	This Webinar is sponsored by Cleveland Dx.

In this webinar, Dr. Hafron reviews recently published data demonstrating the longitudinal predictive value of IsoPSA, showing how test results can guide more confident clinical decisions over time.

Using patient cases, he illustrates how IsoPSA can help clinicians safely defer or extend biopsy intervals in low-risk patients, while identifying those at higher risk who may benefit from closer monitoring.

Dr. Hafron also discusses IsoPSA’s impact on the patient experience, including how it can support shared decision-making and help simplify ongoing care.

Learning Objectives:

• Understand how IsoPSA can enhance clinically significant prostate cancer (csPCa) risk assessment and support shared decision-making.
• Evaluate longitudinal data that demonstrates IsoPSA’s significant clinical value to assess a patient’s future risk of csPCa.
• Apply IsoPSA results to guide patient monitoring and follow-up strategies.

About the speakers:

Jason Hafron, MD, CMO

Michigan Institute of Urology

Dr. Hafron is the Chief Medical Officer and Medical Director of Clinical Research at Michigan Institute of Urology. He is a professor of urology at the William Beaumont School of Medicine, Oakland University in Royal Oak, and is experienced in all areas of adult urology.

Dr. Hafron has published numerous peer‑reviewed journal articles and is on the editorial board of the International Urology and Nephrology journal, Urology Times and Urologists in Cancer Care. He currently serves on the Board of Directors for LUGPA.

He is the recipient of many awards for both his research and clinical work.

This Innovation Theater webinar is a paid program; LUGPA is not liable for the information presented.
Accuracy of the information presented is the responsibility of the advertiser.